Brought to you by 
LifeScan, Novo Nordisk develop diabetes devices
Jun 2001
Executive Summary
Johnson & Johnson subsidiary LifeScan (blood glucose monitoring systems) will work with Novo Nordisk (diabetes therapeutics) in a worldwide collaboration to develop and market diabetes management devices for diabetics administering insulin via daily injections.
Deal Industry
-
In Vitro Diagnostics
- Glucose Testing
-
Medical Devices
- Diagnostic Equipment & Supplies
Deal Status
- Final
Deal Type
-
Alliance
- R+D and Marketing-Licensing
- Co-Marketing
Already a Strategic Transactions subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Related Companies
Advertisement
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
LifeScan, Novo Nordisk develop diabetes devices
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice